Vaxcyte, Inc.
PCVX
$54.58
-$1.63-2.90%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -65.25% | -29.46% | -10.12% | -16.67% | -15.33% |
| Total Depreciation and Amortization | 56.89% | 41.67% | 59.53% | 61.43% | 55.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 78.04% | 114.61% | 107.61% | 270.16% | 260.03% |
| Change in Net Operating Assets | 93.71% | 195.96% | 213.92% | -4,376.50% | -167.50% |
| Cash from Operations | -44.84% | -15.34% | 1.57% | -12.63% | -52.51% |
| Capital Expenditure | 52.19% | 46.25% | 9.39% | -80.03% | -75.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 126.20% | 88.12% | -186.64% | -84.84% | -167.43% |
| Cash from Investing | 121.81% | 83.93% | -143.37% | -84.38% | -159.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.47% | -99.37% | 56.05% | 15.77% | 282.61% |
| Repurchase of Common Stock | 23.10% | 35.20% | -112.06% | -268.73% | -268.73% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -100.00% | 23.07% | -- |
| Cash from Financing | -99.92% | -99.82% | 55.45% | 15.15% | 282.69% |
| Foreign Exchange rate Adjustments | 472.54% | 141.98% | -13.90% | -589.95% | 106.37% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,184.11% | -252.19% | -1,645.20% | -214.33% | 97.86% |